Stock Hero Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator bulldurham, TraderpennyX, Peacefulwendy, TheBestInvest, $Pistol Pete$, KitchenRat
Search This Board:
Last Post: 4/27/2015 5:57:03 PM - Followers: 535 - Board type: Free - Posts Today: 17

Welcome to PharmaCyte BioTech
FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer

ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award

Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)


PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851

Market Value:
$76,201,902 a/o Mar 11, 2015

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

529,206,849 a/o Aug 26, 2014

Short Selling Data

Short Interest: 363,107 (1.685) a/o Feb 13, 2015

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 


All News Releases:

All Information about Nuvilex:

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.


Austria Nova Demonstration Video


SMMG Radio Interview with COO Dr. Crabtree ~ 2013

Shareholder Update with CEO & COO via SMMG Interview ~ July 2014

The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool

Management Team:


Kenneth L. Waggoner, Chief Executive Officer and President:

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.


Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:

Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Dr. Matthias Lohr as Chairman of Scientific Advisory Board:

Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Thomas Liquard - Chairman of the Audit Committe

Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.


Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development


Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy.  In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company.  Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation.  This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology.  Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes.  Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation.  She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings.  Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).



Stock Chart
Company Info
Recent News
Filings and Disclosure
Short Sales
Insider Disclosure
Research Reports
Historical Prices
Interactive Chart
Basic Chart
Basic Tech. Analysis
Press Releases
Company Profile
Key Statistics
Major Holders
Insider Transactions
Insider Roster
Income Statement
Balance Sheet
Cash Flow
Market Watch
OTC Short Report




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVLX News: Current Report Filing (8-k) 01/09/2015 11:34:14 AM
NVLX News: Nuvilex Announces Name Change to PharmaCyte Biotech 01/07/2015 09:30:00 AM
NVLX News: Nuvilex to Attend 2015 Gastrointestinal Cancers Symposium in San Francisco, January 15-17, 2015 01/06/2015 09:30:00 AM
NVLX News: FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment 12/22/2014 08:30:00 AM
NVLX News: Nuvilex’s Partner Austrianova Successfully Completes First Live-Cell Encapsulation in New Facility 12/18/2014 09:30:00 AM
#35210  Sticky Note $PMCB ~ PharmaCyte Biotech, Inc. due diligence report[/b $Pistol Pete$ 04/23/15 08:29:31 PM
#34465  Sticky Note Pancreatic Cancer Drug Works Against Accumulation of Malignant Peacefulwendy 04/14/15 05:14:40 PM
#33559  Sticky Note PharmaCyte Biotech Inc. >>> Insulin / Type 1 TraderpennyX 04/01/15 06:31:41 AM
#31958  Sticky Note PharmaCyte Biotech Initiates Expanded Follow-up Study in the bulldurham 02/19/15 09:31:41 AM
#31423  Sticky Note PharmaCyte Biotech Initiates First Preclinical Study of Its TheBestInvest 02/04/15 11:38:18 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#35292   so if I post it about PMCB it thenewmixer 04/27/15 05:57:03 PM
#35291   Why are you posting misleading info? Are you dustin2333 04/27/15 05:51:14 PM
#35290   Yeah , WHAT ????? Are you ok ???? snowcrab75 04/27/15 05:46:17 PM
#35289   What? Carson1 04/27/15 03:26:31 PM
#35288   PMCB big NEWS within 30 days get in thenewmixer 04/27/15 02:45:25 PM
#35287   R U aware of the specific study for dealerschool2006 04/27/15 12:35:52 PM
#35285   Ok, lets agree to disagree and no longer communicate. BioNewton 04/27/15 10:49:03 AM
#35284   documented as working? where have you seen that thenewmixer 04/27/15 10:41:15 AM
#35283   I have misleading info? Ok. Yes, BioNewton 04/27/15 10:34:18 AM
#35282   PMCB curing Diabetes is about 2 to 4 thenewmixer 04/27/15 10:26:30 AM
#35281   It's Day 67 of the mice study. BioNewton 04/27/15 10:15:23 AM
#35280   can you post a link to that info thenewmixer 04/27/15 09:58:52 AM
#35279   The real news is still living. Long BioNewton 04/27/15 09:54:52 AM
#35278   repeat PMCB PR where is the real news thenewmixer 04/27/15 09:41:57 AM
#35277   Ok Peeps, everyone check your scuba gear and TheSaint09 04/27/15 09:33:20 AM
#35276 BioNewton 04/27/15 09:22:43 AM
#35275   $PMCB chart $Pistol Pete$ 04/26/15 11:42:51 PM
#35272   Thanks for the link Maybe they already start using $Pistol Pete$ 04/26/15 12:36:05 PM
#35271   Check this out Harvard Doctor has cure too, gonetopot 04/26/15 11:28:17 AM
#35270   $PMCB Fri, 17 Apr 2015 08:19:20 GMT ~ $Pistol Pete$ 04/25/15 08:49:09 PM
#35269   PMCB outtrader PMCB thenewmixer 04/25/15 06:30:17 PM
#35266   pmcb mick 04/25/15 04:38:10 PM
#35265   Nice chart Mick and thanks for sharing. Go $PMCB $Pistol Pete$ 04/25/15 04:36:39 PM
#35264 mick 04/25/15 03:34:51 PM
#35263   i think fatfinger could be possibly by may mick 04/25/15 02:22:15 PM
#35262   $PMCB chart showed it should get to $.19 $Pistol Pete$ 04/25/15 02:16:51 PM
#35261   Pharmacyte Biotech, (PMCB) mick 04/25/15 01:27:33 PM
#35260   In my opinion if you have done DD Deborah1 04/25/15 01:18:31 PM
#35259   still sticking with this.... moymsk 04/25/15 10:43:13 AM
#35258   newbe here, chart not looking very good --- CAJUN 04/24/15 07:34:16 PM
#35257   Newbe here------What time period? CAJUN 04/24/15 07:21:13 PM
#35256   Have a good weekend Mick and Everyone! $Pistol Pete$ 04/24/15 05:09:01 PM
#35255   PMCB 30 days time period is over unless thenewmixer 04/24/15 04:13:07 PM
#35253   on 'PharmaCyte Biotech Inc. (PMCB)' CAT IS STILL mick 04/24/15 02:23:50 PM
#35252   How do you figure this to be the Dividend_dude 04/24/15 02:22:46 PM
#35251   Agreed Go $PMCB MAJOR NEWS ANYTIME $Pistol Pete$ 04/24/15 02:21:57 PM
#35250   Is this a fact or just your gut Dividend_dude 04/24/15 02:19:47 PM
#35249   solid trading all wk. pmcb mick 04/24/15 02:17:08 PM
#35248   Thanks for the details Mick Go $PMCB $Pistol Pete$ 04/24/15 02:15:08 PM
#35247   Agreed Go $PMCB $Pistol Pete$ 04/24/15 02:14:46 PM
#35246   Pharmacyte Biotech, (PMCB) mick 04/24/15 02:13:38 PM
#35245   BIG NEWS coming out Monday maybe after hours. If PiieTwo 04/24/15 01:52:42 PM
#35243   Buy low Sell high! TraderpennyX 04/24/15 11:25:49 AM
#35242   Always such good DD Rudy... Thanks Peacefulwendy 04/24/15 10:59:30 AM
#35241   Manipulate $PMCB up and down for a quick $Pistol Pete$ 04/24/15 10:57:49 AM
#35240   where are the sellers ? wilmots 04/24/15 10:14:42 AM
#35239   PMCB looks good. TraderpennyX 04/24/15 10:13:11 AM
#35238   at least not until Pfizer, Bayer, Merck or thenewmixer 04/24/15 10:04:45 AM
#35237   Nice find. Real info. Everything else BioNewton 04/24/15 09:42:54 AM
#35236   when you own shares and follow a company thenewmixer 04/24/15 09:40:16 AM